5 diciembre 2014
Researchers have completed a critical step in the journey from a basic science discovery in the lab to a potential clinical application by showing an experimental agent prevents tumor growth and spread in mice with prostate cancer harboring a common chromosomal abnormality. The agent, YK-4-279, is the first drug targeted at the chromosomal translocations found in about half of prostate cancer cells.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/2QWuAWp46z4/141205142422.htm
